Literature DB >> 9750252

Construction of a continuous stopping boundary from an alpha spending function.

R A Betensky1.   

Abstract

Lan and DeMets (1983, Biometrika 70, 659-663) proposed a flexible method for monitoring accumulating data that does not require the number and times of analyses to be specified in advance yet maintains an overall Type I error, alpha. Their method amounts to discretizing a preselected continuous boundary by clumping the density of the boundary crossing time at discrete analysis times and calculating the resultant discrete-time boundary values. In this framework, the cumulative distribution function of the continuous-time stopping rule is used as an alpha spending function. A key assumption that underlies this method is that future analysis times are not chosen on the basis of the current value of the statistic. However, clinical trials may be monitored more frequently when they are close to crossing the boundary. In this situation, the corresponding continuous-time boundary should be used. Here we demonstrate how to construct a continuous stopping boundary from an alpha spending function. This capability is useful in the design of clinical trials. We use the Beta-Blocker Heart Attack Trial (BHAT) and AIDS Clinical Trials Group protocol 021 for illustration.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9750252

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  2 in total

1.  A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens.

Authors:  Peter B Gilbert; Douglas Grove; Erin Gabriel; Ying Huang; Glenda Gray; Scott M Hammer; Susan P Buchbinder; James Kublin; Lawrence Corey; Steven G Self
Journal:  Stat Commun Infect Dis       Date:  2011-10

2.  Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.

Authors:  Patrick Royston; Friederike M-S Barthel; Mahesh Kb Parmar; Babak Choodari-Oskooei; Valerie Isham
Journal:  Trials       Date:  2011-03-18       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.